基諾華生物科技公司與三軍總醫院合作進行「DF-201」配方運用在糖尿病患者的血糖調控及降低糖化血色素(HbA1c)效果評估，2021年11月11日在三軍總醫院舉行計畫成果發表會，宣布人體臨床實驗解盲成功。

The human clinical trial conducted by Genova Biotechnology Co., Ltd. in cooperation with the Tri-Services General Hospital; the application of DF201 products in the blood sugar regulation of diabetic patients and the evaluation of the effect of reducing glycosylated hemoglobin (HbA1c) has completed in July 2021. On November 11, Geninova held a news conference announcing the successful results at the Tri-Services General Hospital.

基諾華生物科技公司董事長段美南表示，此研究計畫主要產品為「DF-201」，是食品等級的營養品配方，成分包含綠咖啡豆萃取物、苦瓜萃取物、芹菜萃取物、酵母萃取物、西印度櫻桃萃取物、葡萄萃取物、綠茶萃取物、益生菌等為純天然植物萃取物。研究的目的是針對糖尿病患者在常規降血糖藥物治療下，同時搭配服用「DF-201」配方後研究糖化血色素的變化。

Tuan Mei-Nan, President of Geninova Biotech Inc, said that the main product of this research project is "DF-201", which is a food-grade nutritional product. The ingredients include green coffee bean extract, bitter melon extract, celery extract, yeast extract, Acerola cherry extract, grape extract, green tea extract, and probiotics, pure natural plant extracts. The purpose of the research is to study the changes of glycosylated hemoglobin after taking "DF-201" food in combination with the treatment of conventional blood-sugar-lowering drugs for diabetic patients.

此研究計畫於三軍總醫院進行(案號：B202005093)，由三總整形外科戴念梓醫師主導，共收治40位糖尿病友做臨床實驗，自2020年6月15日至2021年7月21日，歷經1年多時間完成全部試驗，期終解盲報告證實「DF-201」配方運用在糖尿病患者的血糖調控及降低糖化血色素(HbA1c)的效果。

This study received approval and started in Tri-Service General Hospital (Case No: B202005093), led by Tri-Service General Hospital Surgery Minister Dr. Dai, Nian-Tzi. A total of 40 diabetic patients had admitted for clinical trials. The event began from June 15th of 2020 to July 21st of 2021. It took more than one year to complete. The final report confirmed the effectiveness of "DF-201" products in diabetic patients effectively to regulate blood sugar and reduce glycated hemoglobin (HbA1c).

三軍總醫院表示，此次與基諾華生物科技公司合作進行人體試驗能夠成功完成，除了試驗配方的本身效果外，更重要的是糖尿病友的全人醫療照護、糖尿病衛教士的輔導與研究計畫醫師群的支持。從糖友的回饋報告中得知，許多受試者的生活品質明顯改善，糖友們內心充滿感謝。

The Tri-Services General Hospital said that the human trial was successfully completed. In addition to the effects of the test product itself, the more important thing was the holistic care of diabetics, the support from diabetes Mentors, and the research program physician group. The subjects were grateful to have learned that their quality of life had improved significantly from the reports of diabetic patients.

三總提醒，糖尿病的治療需從公共衛生角度推動相關防治政策，而不僅是單純的醫療問題，包含如何養成正確的飲食觀念、培養規律的運動習慣、時時小心監測血糖問題、早期發現、適當治療，這樣才可以打敗糖尿病。

Tri-Service General Hospital official reminds the public that the treatment of diabetes needs to promote related prevention and treatment policies from a public health perspective. It's not just a purely medical problem. It has to include developing a correct dietary concept, cultivating regular exercise habits, and carefully monitoring blood sugar problems from time to time. Early Discovery and proper treatment so that the patients can defeat diabetes.

感謝各界支持本次糖尿患者的人體臨床試驗，由衷感謝醫師及教授們的付出，更感謝糖尿病友們得配合，讓我們一起為全世界人民的健康努力向前！

Thanks all for supporting this human clinical trial for patients with diabetes. Sincerely, thank the doctors and professors for their contributions. Thank the diabetic patients for their cooperation. Let us work wisely for the health of people worldwide!